Gamma-linolenic-acid oils for rheumatoid arthritis: moderate evidence, not a DMARD replacement
Borage, evening-primrose and blackcurrant oils contain GLA and have rheumatoid-arthritis trials, but products and background care differ.
THE EVIDENCE FOR
MOVING WELL.
Borage, evening-primrose and blackcurrant oils contain GLA and have rheumatoid-arthritis trials, but products and background care differ.
L-carnitine trials report pain and function signals, but overlapping samples, mediocre study quality and heterogeneity limit confidence.
A 2026 review found possible modest melatonin benefits for musculoskeletal pain and sleep, but fibromyalgia trials remain small and varied.
Red-yeast-rice trials and safety reviews conflict, while variable monacolin K and citrinin contamination complicate real-world use.
A multicenter phase 3 trial found resveratrol no better than placebo for knee pain, despite favorable signals in another frailty-focused study.
A 2026 saffron trial reported lower inflammatory markers and NSAID use, while pain improved in both groups and study limitations remain.
Thunder-god vine trials report rheumatoid-arthritis activity, but kidney, liver, reproductive and blood-cell risks make self-treatment unsafe.
Recent randomized trials of oral CBD for knee and hand osteoarthritis did not beat placebo, and one high-dose study found more adverse events.
CoQ10 reviews disagree about statin-associated muscle pain, while a rigorous confirmation trial found no benefit in verified cases.
Devil’s claw trials suggest possible short-term symptom relief, but formulation differences, weak methods and limited safety data constrain conclusions.
A 2024 meta-analysis found small average improvements from eggshell membrane, while individual trials and allergy questions limit broad claims.
A 2026 frailty trial reported functional gains from HMB, while a 2026 meta-analysis found no routine benefit with resistance training.